Sign in
Matthew Aspro

Matthew Aspro

Research Analyst at Jefferies Financial Group Inc.

United States

Matthew Aspro is an Equity Associate at Jefferies LLC specializing in equity research, with recent coverage including companies such as Allurion Technologies in the medical supplies and devices sector. Since joining Jefferies in 2024, Aspro has contributed to investment analysis and research, leveraging previous experience as an Analyst at Davis-Rea Ltd. from 2021 to 2024 and other roles in investment analysis, equity derivatives sales, and treasury markets. He holds FINRA registration as a broker with Jefferies and has a background indicative of relevant securities licensing. Aspro's analytical work supports key investment decisions and client communications within the firm.

Matthew Aspro's questions to STRYKER (SYK) leadership

Question · Q2 2025

Matthew Aspro of Jefferies asked about the implications of the recent OB VBA bill on hospital purchasing behavior and the outlook for Stryker's tax rate into 2026.

Answer

VP of Finance & IR Jason Beach stated that Stryker is monitoring the bill but sees minimal impact as Medicaid is a small part of its procedure base and capital demand remains tied to strong procedure volumes. VP & CFO Preston Wells noted that while the bill may provide a cash tax benefit, he does not expect a significant impact on the company's effective tax rate (ETR), which should remain in a similar range to the current 15-16% guide.

Ask follow-up questions

Fintool

Fintool can predict STRYKER logo SYK's earnings beat/miss a week before the call

Let Fintool AI Agent track Matthew Aspro for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free